A respiratory syncytial virus (RSV) vaccine based on parainfluenza virus 5 (PIV5)

作者：Phan Shannon I; Chen Zhenhai; Xu Pei; Li Zhuo; Gao Xiudan; Foster Stephanie L; Teng Michael N; Tripp Ralph A; Sakamoto Kaori; He Biao^*

来源：Vaccine, 2014, 32(25): 3050-3057.

DOI：10.1016/j.vaccine.2014.03.049

• Vaccine
• Respiratory syncytial virus
• Parainfluenza virus 5

Human respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease and hospitalizations in infants and young children. It also causes significant morbidity and mortality in elderly and immune compromised individuals. No licensed vaccine currently exists. Parainfluenza virus 5 (PIV5) is a paramyxovirus that causes no known human illness and has been used as a platform for vector-based vaccine development. To evaluate the efficacy of PIV5 as a RSV vaccine vector, we generated two recombinant PIV5 viruses - one expressing the fusion (F) protein and the other expressing the attachment glycoprotein (G) of RSV strain A2 (RSV A2). The vaccine strains were used separately for single-dose vaccinations in BALB/c mice. The results showed that both vaccines induced RSV antigen-specific antibody responses, with IgG2a/IgG1 ratios similar to those seen in wild-type RSV A2 infection. After challenging the vaccinated mice with RSV A2, histopathology of lung sections showed that the vaccines did not exacerbate lung lesions relative to RSV A2-immunized mice. Importantly, both F and G vaccines induced protective immunity. Therefore, PIV5 presents an attractive platform for vector-based vaccines against RSV infection.

• 出版日期2014-5-23